Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects

American Journal of Hypertension

Volumn 12, Issue 6, 1999, Pages 563-571

  Norton, Gavin R ^a   Woodiwiss, Angela J ^a   Hartford, Craig ^a   Trifunovic, Boris ^a   Middlemost, Shirley ^a   Lee, Andrew ^c   Allen, Michael J ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c Pfizer Limited   (South Africa)

Author keywords

24 Hour ambulatory blood pressure; Angiotensin converting enzyme; Atrial natriuretic peptide; Essential hypertension

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; METALLOPROTEINASE INHIBITOR; RENIN; SAMPATRILAT; UNCLASSIFIED DRUG;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; EDEMA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEGRO; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION;

EID: 0033059782     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(99)00009-6     Document Type: Article

References (23)

1. Luparini R.L., Ferri C., Santucci A., Balsano F. Atrial natriuretic peptide in non-modulating essential hypertension. Hypertension. 21:1993;803-809.
2. MacGregor G.A., Sagnella G.A., Markandu N.D., et al. Raised plasma levels of atrial natriuretic peptide in subjects with untreated essential hypertension. J Hypertens. 4:(suppl 6):1986;S567-S569.
3. Janssen W.M.T., De Zeeuw D., van der Hem G.K., de Jong P.E. Antihypertensive effect of a 5-day infusion of atrial natriuretic factor in humans. Hypertension. 13:1989;640-646.
4. 126) reduces blood pressure in conscious SHR without apparent changes in sodium excretion. Proc Soc Exp Biol Med. 179:1985;396-401.
5. Northbridge D.B., Alabaster C.T., Connell J.M.C., et al. Effects of UK 69 578 a novel atriopeptidase inhibitor . Lancet. ii:1989;591-593.
6. Gros C., Souque A., Schwartz J.-C., et al. Protection of atrial natriuretic factor against degradation diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan . Proc Natl Acad Sci USA. 86:1989;7580-7584.
7. Lefrancois P., Clerc G., Duchier G., et al. Antihypertensive activity of sinorphan. Lancet. 336:1990;307-308.
8. Ogihara T., Rakugi H., Masuo K., et al. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens. 7:1994;943-947.
9. Kosoglou T., Herron J.M., Chen R., et al. Antihypertensive effects of the atriopeptidase inhibitor SCH 34826 in essential hypertension. Circulation. 82:(suppl 3):1990;554. (abstr).
10. Richards A.M., Crozier I.G., Espiner E.A., et al. Acute inhibition of endopeptidase 24.11 in essential hypertension SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure . J Cardiovasc Pharmacol. 20:1992;735-741.
11. Richards A.M., Crozier I.G., Kosoglou T., et al. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension. 22:1993;119-126.
12. Bevan E.G., Connell J.M.C., Doyle J., et al. Candoxatril, a neutral endopeptidase inhibitor efficacy and tolerability in essential hypertension . J Hypertens. 10:1992;607-613.
13. Richards A.M., Wittert G.A., Espiner E.A., et al. Effect of inhibition of endopeptidase 24.11 on response to angiotensin II in human volunteers. Circ Res. 71:1992;1501-1507.
14. Favrat B., Burnier M., Nussberger J., et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens. 13:1995;797-804.
15. Cruickshank J.M., Lewis J., Moore V., Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens. 6:1992;85-90.
16. Middlemost S.J., Tager R., Davis J., Sareli P. Effectiveness of enalapril in combination with low-dose hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in blacks. Am J Cardiol. 73:1994;1092-1097.
17. Saunders E. Tailoring treatment to minority patients. Am J Med. 88:(suppl 3B):1990;21S-31S.
18. Mancia G., Omboni S., Parati G., et al. Ambulatory blood pressure monitoring in the design of studies on antihypertensive drug efficacy. Am J Hypertens. 6:(suppl):1993;233S-235S.
19. White W.B., Grinn J.M., McCabe E.J. Clinical usefulness of ambulatory blood pressure monitoring. Am J Hypertens. 6:(suppl):1993;225S-228S.
20. Stergiou G.S., Hannah J.A., Bevan L.S.A., et al. Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients. J Hypertens. 12:1994;1310-1311.
21. Tunny T.J., Ziesak M.D., Armstrong R., et al. Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension. J Hypertens. 11:(suppl 5):1993;S222-S223.
22. Cummings D.M., Amadio P. Jr, Taylor E.M. Jr, et al. The antihypertensive response to lisinopril the effect of age in a predominantly black population . J Clin Pharmacol. 29:1989;25-32.
23. Wilkins M.R. Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease. Biochem Soc Transact. 21:1993;673-678.